Q-omics provides the consensus-scored RPS3AP20 profile across patient tissues and cancer cell-line models. RPS3AP20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS3AP20 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPS3AP20 RNA expression shows 16,268 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRC, and ACC as cancer lineages where RPS3AP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3AP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3AP20 survival associations across molecular data types. RPS3AP20 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3AP20 RNA expression–survival associations across cancer types. High RPS3AP20 expression shows unfavorable associations in LIHC, ACC, OV, KICH and UVM, but favorable associations in LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS3AP20 RNA expression.
This table summarizes RPS3AP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS3AP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3AP20 shows lower tumor expression in BRCA and KICH and higher tumor expression in KIRC, COAD, LIHC and CHOL. The KIRC box plot shows higher RPS3AP20 RNA expression in tumor versus normal tissue (log2 FC = +0.492, t-test p < 0.001).
This table shows molecular features associated with RPS3AP20 in patient tissues and cancer cell lines. In patient samples, RPS3AP20 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
